A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Novo Nordisk A S stock. As of the latest transaction made, Citadel Advisors LLC holds 1,153,700 shares of NVO stock, worth $121 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
1,153,700
Previous 1,407,200 18.01%
Holding current value
$121 Million
Previous $201 Million 31.61%
% of portfolio
0.03%
Previous 0.04%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$119.07 - $145.42 $54.9 Million - $67.1 Million
-461,465 Reduced 52.85%
411,641 $49 Million
Q2 2024

Aug 14, 2024

SELL
$122.71 - $146.91 $11.7 Million - $14.1 Million
-95,718 Reduced 9.88%
873,106 $125 Million
Q1 2024

May 15, 2024

BUY
$102.11 - $135.92 $44.3 Million - $58.9 Million
433,417 Added 80.95%
968,824 $124 Million
Q4 2023

Feb 14, 2024

BUY
$87.78 - $105.45 $18.2 Million - $21.8 Million
207,041 Added 63.05%
535,407 $55.4 Million
Q3 2023

Nov 14, 2023

BUY
$90.94 - $199.54 $10 Million - $22 Million
110,246 Added 50.54%
328,366 $29.9 Million
Q2 2023

Aug 14, 2023

SELL
$155.98 - $172.65 $1.85 Million - $2.05 Million
-11,875 Reduced 5.16%
218,120 $35.3 Million
Q1 2023

May 15, 2023

SELL
$132.34 - $159.14 $23.3 Million - $28 Million
-175,803 Reduced 43.32%
229,995 $36.6 Million
Q4 2022

Feb 14, 2023

BUY
$102.55 - $135.33 $10.5 Million - $13.8 Million
102,333 Added 33.72%
405,798 $54.9 Million
Q3 2022

Nov 14, 2022

SELL
$95.28 - $116.93 $13.4 Million - $16.5 Million
-140,737 Reduced 31.68%
303,465 $30.2 Million
Q2 2022

Aug 15, 2022

BUY
$103.24 - $121.81 $40 Million - $47.2 Million
387,523 Added 683.72%
444,202 $49.5 Million
Q1 2022

May 16, 2022

BUY
$93.1 - $112.54 $996,635 - $1.2 Million
10,705 Added 23.28%
56,679 $6.29 Million
Q4 2021

Feb 14, 2022

SELL
$95.88 - $117.08 $29.9 Million - $36.6 Million
-312,213 Reduced 87.16%
45,974 $5.15 Million
Q3 2021

Nov 15, 2021

BUY
$84.42 - $106.62 $11.5 Million - $14.5 Million
135,708 Added 61.0%
358,187 $34.4 Million
Q2 2021

Aug 16, 2021

SELL
$67.66 - $84.76 $303,455 - $380,148
-4,485 Reduced 1.98%
222,479 $18.6 Million
Q1 2021

May 17, 2021

SELL
$67.06 - $75.82 $16.1 Million - $18.2 Million
-240,289 Reduced 51.43%
226,964 $15.3 Million
Q4 2020

Feb 16, 2021

BUY
$63.89 - $73.8 $6.99 Million - $8.07 Million
109,371 Added 30.56%
467,253 $32.6 Million
Q3 2020

Nov 16, 2020

BUY
$63.69 - $70.22 $13 Million - $14.3 Million
203,523 Added 131.85%
357,882 $24.8 Million
Q2 2020

Aug 14, 2020

BUY
$58.54 - $67.94 $8.12 Million - $9.43 Million
138,788 Added 891.32%
154,359 $10.1 Million
Q1 2020

May 15, 2020

SELL
$49.46 - $64.78 $11.4 Million - $14.9 Million
-230,167 Reduced 93.66%
15,571 $937,000
Q4 2019

Feb 14, 2020

SELL
$49.86 - $58.26 $1.55 Million - $1.81 Million
-31,017 Reduced 11.21%
245,738 $14.2 Million
Q3 2019

Nov 14, 2019

SELL
$47.54 - $53.43 $26.6 Million - $29.9 Million
-559,491 Reduced 66.91%
276,755 $14.3 Million
Q2 2019

Aug 14, 2019

BUY
$46.79 - $52.47 $15.6 Million - $17.4 Million
332,358 Added 65.96%
836,246 $42.7 Million
Q1 2019

May 15, 2019

BUY
$46.36 - $52.63 $22.5 Million - $25.5 Million
484,499 Added 2498.83%
503,888 $0
Q4 2018

Feb 14, 2019

SELL
$41.54 - $47.25 $6.46 Million - $7.35 Million
-155,461 Reduced 88.91%
19,389 $893,000
Q3 2018

Nov 13, 2018

BUY
$46.76 - $51.24 $5.69 Million - $6.24 Million
121,766 Added 229.38%
174,850 $0
Q2 2018

Aug 10, 2018

SELL
$44.29 - $50.42 $7.79 Million - $8.87 Million
-175,985 Reduced 76.83%
53,084 $0
Q1 2018

May 11, 2018

BUY
$48.49 - $58.14 $6.18 Million - $7.41 Million
127,410 Added 125.33%
229,069 $11.3 Million
Q4 2017

Feb 09, 2018

SELL
$47.53 - $53.73 $7.47 Million - $8.45 Million
-157,193 Reduced 60.73%
101,659 $5.46 Million
Q3 2017

Nov 09, 2017

BUY
$41.15 - $49.22 $10.7 Million - $12.7 Million
258,852
258,852 $12.5 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $238B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.